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INTRODUCTION 
 
Normal growth: 
Growth can be defined as a process of increase in size by 
accretion of tissue. It is observed in the whole organism, in body 
regions, in organ systems, and in the cellular environment. Human 
growth starts at conception and proceeds through various identifiable 
developmental stages. It is dependent on cell hyperplasia (an increase 
in cell number), cell hypertrophy (an increase in cell size) and 
apoptosis (programmed cell death). Hyperplasia and apoptosis are 
genetically regulated to limit the size of an organ or the body.  
The process of growth is complex. The process of growth 
depends on both genetic and environmental factors that combine to 
determine an individual's eventual height. 
 The genetic control of statural growth is becoming increasingly 
clear. Many genes have been identified that are required for normal 
development and function of the pituitary and that control the growth 
hormone/insulin-like growth factor axis in particular. So every child 
grows normally in predictable manner. Hence longitudinal assessment 
of all children’s growth is essential for all paediatric practice. The 
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most common referral to paediatric endocrinologist is a concern of 
growth failure.  
 
Definition: 
 A child is considered to be short when his /her height is below 
the 3rd centile on a height chart for the specific population . It is 
important to use country specific updated growth charts so that 
appropriate population standards are applied and over diagnosis of 
short stature is avoided. While using growth charts,  parents’ heights 
should be considered and adjusted midparental height (MPH)(sex 
Specific target height )should be plotted. 
 
 Factors affecting human growth: 
         Linear growth of an individual and final adult height is 
determined by his/her genetic potential. However true realization of 
one’s growth potential depends upon general well being, nutrition and 
hormonal mileu like growth hormone, thyroid hormone, insulin like 
growth factor 1,2, IGFBP3. 
 From weeks 4 to 8, there is rapid growth and differentiation to 
form all the major organ systems in the body. In the second trimester, 
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the fetus undergoes major cellular hyperplasia and in the third, organ 
systems mature in preparation for extrauterine life. 
Throughout gestation, fetal growth is constrained by maternal 
factors and placental function but is co-ordinated by growth factors [2]. 
These can act locally in a paracrine manner [eg. IGF-I and IGF-II, 
fibroblast growth factor, epidermal growth factor, transforming 
growth factors α and β] or as endocrine hormones (e.g. insulin). 
Nutrition from the mother plays a rate-limiting role. 
During the first year, infants grow rapidly but at a sharply 
decelerating rate [1,3]. A similar pattern is observed for weight gain. It 
has been postulated that nutritional input is the principal regulator of 
growth over this period with minimal contribution from growth 
hormone.  
Data from humans and transgenic animal models suggest that 
the hormones and receptors within the GH–IGF axis also play their 
part in this early phase of growth. Nevertheless, it is during this period 
that alterations in dietary intake are likely to have the greatest impact 
on growth. Although growth charts give the impression that growth is 
linear, most studies of short-term growth (day to day, week to week) 
find it to be non-linear [4]. 
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By 4 years of age, average growth velocity has declined to 7 
cm/year and remains relatively steady until adolescence, the 
prepubertal nadir in average velocity being 5 to 5.5 cm/year. On an 
individual basis, there is a well-recognized mid-childhood growth 
spurt. Additionally, if an individual is measured throughout childhood, 
oscillations in growth velocity of variable amplitude are observed 
With a periodicity of approximately 2 years [5]. 
During childhood, growth hormone, in addition to thyroid 
hormone, is the major determinant of growth. It is therefore the time 
when dysfunction in the GH axis may be recognized. There is also 
wide variation in pubertal timing within each sex. The later onset of 
puberty in boys gives them two additional years of prepubertal growth 
compared with girls. 
 The height gained in this time (8–10 cm), in addition to the 
greater amplitude of pubertal growth in boys (3–5 cm more than the 
female growth spurt), gives rise to the 12.5 cm difference in adult 
height between the sexes. 
 Constitutional delay of growth and puberty is common and can 
be considered a variant of normal. The condition can be associated 
with chronic disease, for example atopy, but more often occurs in 
isolation. Pubertal development commences late and the growth spurt 
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is blunted. Although constitutional delay in growth and puberty may 
actually present in the pubertal years, some children may have shown 
slow growth much earlier in childhood. The corollary is constitutional 
tall stature and early puberty, which is associated with more intense 
pubertal growth than normal. The net result is that both early and late 
maturers should achieve a comparable height. 
 The degree of physical development and the timing of the 
pubertal growth spurt complicate assessment of growth velocity 
around puberty(6). It is this variation that gives rise to the wide 
variation in peak height velocity on growth charts.  
 
The endocrine control of growth: 
The principal hormones influencing growth are GH and the 
IGFs, but there are many other hormones that contribute, including 
thyroid hormones, adrenal androgens, sex steroids, glucocorticoids, 
vitamin D, leptin, and insulin. Often, this contribution is channeled 
through interaction with the GH–IGF axis.  
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Hypothalamic control of GH secretion: 
Growth hormone is secreted from the anterior pituitary in 
discrete pulses every 3–4 hr, with very low concentrations of growth 
hormone present between pulses. This pattern is determined by the 
interaction between growth hormone-releasing hormone, ghrelin and 
somatostatin[7].  
The amplitude of the GH peak is determined by GHRH. Ghrelin 
acts in synergy with GHRH to promote GH release. Ghrelin also has a 
potent orexigenic action, indicating a link between nutritional and 
growth control. Withdrawal of somatostatin is the most important 
factor in determining the time of a pulse as GH pulsatility is 
maintained under constant infusion of GHRH. 
 
Pituitary control of GH secretion: 
The human GH gene forms part of a cluster of five similar 
genes found on the long arm of chromosome 17 [7]. The main form of 
GH in the circulation comes from the GH-N (or normal) gene 
expressed primarily in the pituitary. The full-length transcript from the 
GH-N gene encodes a 191-amino-acid, 22 kDa protein, which 
constitutes 80–90% of pituitary GH. Alternative splicing of the mRNA 
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transcripts generates a 20 kDa species that lacks amino acids 32–46 
and accounts for the remaining 10–20%. Deletion of the GH-N gene in 
humans leads to severe postnatal growth failure and in these 
individuals; treatment with GH generates a short-lived growth 
response resulting from the development of anti- GH antibodies. 
 
 
Other factors influencing GH secretion: 
Table 8. Physiologic factors that affect GH secretion. 
Factors that stimulate GH 
secretion   
Factors that suppress GH 
secretion  
Exercise   Hypothyroidism  
Stress   Obesity  
Hypoglycemia   Hyperglycemia  
Fasting   High carbohydrate meals  
High protein meals   Excess glucocorticoids  
Sleep (7) 
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Growth hormone in the circulation: 
Serum levels of GH rise to high levels by 24 weeks of gestation, 
decline towards birth and fall further after the first 2 weeks of 
postnatal life. The high concentrations of GH throughout gestation are 
a reflection of the time taken for the neuroendocrine control of GH 
secretion to develop. In early gestation, GH release from the pituitary 
is uncontrolled. The decrease in GH after 24 weeks is then associated 
with the development of the inhibitory mechanisms governing growth 
hormone release. 
Few data exist on the longitudinal changes in GH secretion with 
age in prepubertal children, but cross-sectional data suggest that GH 
pulse amplitude increases with age [8]. The most profound changes in 
GH secretion occur through the pubertal years with a marked increase 
in the amplitude of GH pulses [8]. Androgens and estrogens both 
increase GH secretion during puberty. 
 Maximal levels of GH secretion coincide with the timing of 
peak height velocity in both sexes and secretion declines thereafter 
into adulthood. In pre- pubertal and pubertal children, episodic GH 
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release generates large peaks of GH lasting 1–2 h separated by periods 
of low basal secretion .Trough concentrations of GH are correlated 
with body composition and metabolic parameters, while peak 
concentrations correlate with IGF-I production[9].  
 
Physiological actions of GH and IGF-I on bone growth: 
The major role of GH during growth and development is to 
promote longitudinal bone growth. The somatomedin hypothesis 
proposes that GH mediates its effects on its target tissues via 
stimulation of hepatic IGF-I production, which in turn acts as a 
classical endocrine hormone. In the absence of endocrine IGF-I, 
autocrine and/or paracrine production of IGF-I is sufficient to sustain 
normal growth. 
 The key mediator of GH action in the periphery for both 
prenatal and postnatal mammalian growth is IGF system. GH exerts 
its direct effects at the growth plate and indirect effects via IGF1. 
Better understanding the role of IGF1 on growth had led to the 
concept of IGF1 deficiency in addition to GH deficiency. With the 
introduction of recombinant human (rh) IGF1, it is possible to treat 
conditions due to genetic GH resistance or insensitivity caused by GH 
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receptor defects and the presence of neutralizing GH antibodies (10).  
       The growth-suppressing effects of glucocorticoids are also seen in 
children affected with congenital adrenal hyperplasia(CAH) where 
high androgens limit the height potential. Most patients with CAH 
complete their growth prematurely and are ultimately short adults. 
LinSu,et al., showed that GH in combination with LHRH significantly 
improved their final adult height in children with CAH (11).  
 
Classification of short stature: 
1. Chronic malnutrition 
2. Chronic systemic diseases 
Chronic infections like TB 
Chronic renal failure 
Cardiac diseases 
Respiratory diseases 
Collagen vascular diseases 
Inflammatory bowel disease 
Celiac disease 
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 3. Endocrine causes 
A. GHD, hypothalamic or a pituitary causes 
a. Idiopathic 
b. Genetic 
i. HESX1 
ii. PROP1 
iii. POUF1 (Pit1) 
c.  Mutations within the GH gene 
d. Mutation of the GHRH receptor 
e. Congenital 
i. Associated with structural defects  
a. Agenesis of corpus callosum 
b. Septo-optic dysplasia 
c. Holoprosencephaly 
d. Arachnoid cyst 
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ii. Associated with midline facial defects 
a. Single central incisor 
b. Cleft lip/palate 
c. Nasal dimple 
f. Acquired 
i. Perinatal trauma 
ii. Postnatal trauma 
iii. Central nervous system infections 
iv. Trauma 
v. Cranial irradiation  
g. Primary tumours of hypothalamus or pituitary 
i. Craniopharyngioma 
ii. Glioma/astrocytoma 
iii. Germinoma  
h. Secondary tumours of hypothalamus or pituitary 
i. Histiocytosis 
ii. Lymphoma 
i. Transient  
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 j. Psychosocial deprivation 
 
k. GHD of undefined etiology (idiopathic) (including those 
with abnormal     pituitary morphology on  MRI – 
pituitary hypoplasia, interrupted or hypoplastic  stalk, 
ectopically placed posterior pituitary lobe(12)) 
 
B. Larons dwarfism 
C. Hypothyroidism  
D. Cushing syndrome 
4. Familial short stature 
5. Constituitional growth delay 
6. Chromosomal abnormalities 
7. Disorders of bone disease 
The true incidence of GH deficiency has not been established with 
certainty and its prevalence has been reported to be approximately of 
1:3500 children.  
13 
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Clinical presentations: 
 Idiopathic hypopituitarism can present as an isolated hormone 
deficiency or be part of a combined pituitary hormone deficiency 
syndrome. In the neonatal period infants usually present with normal 
birth weight and birth length but  impairment of linear growth will 
occur in the first two years of life. In the neonatal period, episodes of 
recurrent hypoglycemia, prolonged jaundice or micropenis should 
alert the physician of the possibility of congenital hypopituitarism. 
(13,14). 
GH deficiency can present as an isolated pituitary deficiency or 
can be associated with other pituitary hormone deficiencies, the most 
common being TSH deficiency and less commonly gonadotrophin or 
ACTH deficiencies. Mineralocorticoid deficiency is rare in children 
with hypopituitarism since aldosterone secretion is largely 
independent of pituitary ACTH stimulation. 
 During early childhood, isolated GH deficiency can present 
with a classical phenotype of growth failure, protrusion of the frontal 
bones and poor development of the bridge of the nose. Closure of the  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
anterior fontanel may be delayed and dental eruption and skeletal 
maturation are usually quite delayed. The penis is often small and this 
may be accentuated by the presence of truncal obesity. Delay of 
puberty is frequent. However if gonadotrophin function is intact, 
puberty will develop.  
Acquired  
Perinatal pathology (prenatal infections, trauma) GH deficiency 
associated with congenital rubella, toxoplasmosis and 
cytomegalovirus infections have been described (15). Perinatal trauma 
especially associated with forceps delivery, vaginal bleeding and 
breech presentations (16).  
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Birth history 
 
Gestational age, birth weight and 
length, delivery type, birth trauma, 
hypoglycemia, prolonged 
jaundice.  
Past medical and surgical history 
 
Head trauma, surgery, cranial 
radiation, CNS infection. 
Review of systems 
 
Appetite, eating habits, bowel 
movements. 
Chronic illness 
 
Anemia, Inflammatory Bowel 
Disease, cardiovascular disease, 
renal insufficiency, etc. 
 
Family history 
 
Consanguinity, parents and 
siblings' heights, family history of 
short stature, delayed puberty 
 
Physical examination 
 
Body proportions (upper/lower 
segment ratio, arm span), head 
circumference, microphallus, 
dysmorphism, and midline 
craniofacial abnormalities.  
Growth pattern 
 
Crossing of percentiles, failure to 
catch-up.  
Table 1. Guidelines for initial clinical evaluation of a child with 
short stature (10) 
Evaluation Key elements 
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Growth charts: 
 Commonly used growth charts are the height, weight and BMI 
charts. Similarly height velocity and proportion charts are essential 
tools in the diagnosis of short stature. When growth velocity observed 
over a 6 months or more falls below.  
When growth velocity observed over a period of 6 months or 
more, falls below 25th centile on the velocity chart,  is considered 
abnormal and has more significance than a single height reading 
below the 3rd centile on a distance chart. Growth velocity is a very 
sensitive and reliable way to decide whom to investigate. 
 Height charts are used as a primary screening tool when 
evaluating a child with short stature. When a child is detected to have 
short stature, velocity charts are used to follow his or her progress 
over a period of time.  
In 2007, the Indian Academy of Paediatrics published 
guidelines for growth monitoring incorporating data by Agarwal et al 
for use by pediatricians in India. In 2006 WHO published a 
multination study that provides prescriptive growth charts for children 
under the age of 5 years.(41)  WHO recommends use of these growth 
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charts for all children under the age of 5 years around the world and 
government of India has given a directive for use of these charts for 
under 5 children in India in all areas and across all socio economic 
classes.(42) 
 
 Radiologic evaluation: 
The most commonly used system to assess skeletal maturity is 
to determine the 'bone age' of the left hand and wrist, using the method 
of Greulich and Pyle (17). Children younger than 2 years of age should 
have their bone age estimated from x-rays of the knee. Tanner and 
Whitehouse and their colleagues developed a scoring system for each 
of the hand bones as an alternative method to the method of Greulich 
and Pyle (18). 
 Adult height prediction methods estimate adult height by 
evaluating height at presentation relative to normative values for 
chronological or bone age (19) and are generally considered accurate in 
evaluating healthy children with a normal growth potential (20,21). 
Several different methods have been produced and are currently in 
widespread use, including those of Bayley-Pinneau, the Tanner-
18 
 
Whitehouse-Marshall-Carter and Roche-Wainer-Thissen. 
 Grulich and pyle developed what is commonly known as the 
predicted adult height (PAH) method of Bayley-Pinneau (BP)(22,23). 
The Bayley-Pinneau PAH method is applicable from age 8 years 
onwards. 
 Tanner, Whitehouse, Marshall and Carter developed an adult 
height prediction model based on current height, the mid-parental 
height, the age of menarche in girls and the Tanner bone age. (18) TW2 
differs from the BP method in that the TW2 lowers the minimal age of 
prediction to 4 years; and also allows for a quantitative effect of bone 
age, while Bayley-Pinneau give a semi-quantitative effect of bone age 
(i.e. delayed, normal or advanced). 
 The RWT predicted adult height method assesses the subjects 
height, weight, bone age and midparental height (MPH) and then 
applies regression techniques to determine the mathematical weighting 
to be applied to the four variables(24).  
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Biochemical evaluation of GH deficiency: 
 Several methods have been recommended to assess the adequacy 
of growth hormone secretion:  
1. Stimulation testing: GH provocation utilizing arginine, 
clonidine, glucagon, L-Dopa, insulin, etc. This practice 
generally measures pituitary reserve or GH secretory ability 
rather than endogenous secretory status.  
2. GH-dependent biochemical markers- IGF1 and IGFBP3: 
Values below a cut-off less than -2 SD for IGF1 and/or IGFBP3 
strongly suggest an abnormality in the growth hormone axis if 
other causes of low IGF have been excluded. Age and gender 
appropriate reference ranges for IGF1 and IGFBP3 are 
mandatory. 
3. 24-hour or Overnight GH sampling: Blood sampling at 
frequent intervals designed to quantify physiologic bursts of 
GH secretion. 
4. IGF generation test: This test is used to assess GH action and 
for the confirmation of suspected GH insensitivity. GH is given 
for several days (3-5days) with serum IGF1 and IGFBP3 levels 
measured at the start and end of the test.         A sufficient rise 
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in IGF1 and IGFBP3 levels would exclude severe forms of 
growth hormone insensitivity (100, 25). 
 Failure to raise the serum GH level to the threshold level in 
response to provocation suggests the diagnosis of GH deficiency, 
while a low IGF1 and/or IGFBP3 level is supportive evidence. Puberty 
and administration of the sex steroids increase GH response to 
stimulation tests (27). To prevent false positive results, some centers use 
sex steroid priming in prepubertal children prior to GH stimulation 
testing (28). In obese children, the normal regulation of the GH/IGF1 
axis is disturbed and GH secretion is decreased. In addition, IGF1 
levels are very sensitive to the nutritional status (IGFBP3 less so), and 
also that the normative range for IGF1 and IGFBP3 values are 
extremely wide, often with poor discrimination between normal and 
pathological. 
 
 Summary of diagnosis of GH deficiency: 
Children with severe GH deficiency can usually be diagnosed 
easily on clinical grounds and fail  GH stimulation tests. Studies have 
shown that despite clinical evidence of GH deficiency, some children 
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may pass GH stimulation tests (100). In the case of unexplained short 
stature, if the child meets most of the following criteria, a trial of GH 
treatment should be initiated (26). 
1. Height >2.25 SD below the mean for age or >2 SD below 
the midparental height    percentile. 
2. Growth velocity <25th percentile for bone age. 
3. Bone age >2 SD below the mean for age 
4. Low serum insulin-like growth factor 1 (IGF1) and/or 
insulin like growth factor binding protein 3 (IGFBP3) 
5.  Other clinical features suggestive of GH deficiency.  
Key elements that may indicate GH deficiency are:  
1. Height more than 2 SD below the mean. 
2.  Neonatal hypoglycemia, microphallus, prolonged jaundice, or 
traumatic delivery.  
3. Although not required, a peak GH concentration after 
provocative GH testing of less than 10 ng /ml.  
4. Consanguinity and/or a family member with GH deficiency.  
22 
 
5. Midline CNS defects, pituitary hypo or aplasia, pituitary stalk 
agenesis, empty sella, ectopic posterior pituitary (bright spot) on 
MRI.  
6. Deficiency of other pituitary hormones: TSH, Prolactin, 
LH/FSH and/or ACTH deficiency. 
 Many practitioners consider GH stimulation tests to be optional 
in the case of clinical evidence of GH deficiency, in patients with a 
history of surgery or irradiation of the hypothalamus/pituitary region 
and growth failure accompanied by additional pituitary hormone 
deficiencies. Similarly children born SGA, Turner syndrome, Prader 
willi syndrome and chronic renal insufficiency do not require GH 
stimulation testing before initiating GH treatment (26).  
Treatment: 
The principal objective of GH treatment in children with GH 
deficiency is to improve final adult height. 
 Administration of rhGH in the evening is designed to mimic 
physiologic hGH secretion. Treatment is continued until final height 
or epiphyseal closure (or both) has been recorded.  
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It is critically important to maximize height with GH therapy 
before the onset of puberty. Several investigators have advocated 
modifying puberty or the production of estrogens by the use of GnRH 
super-analogues (29, 30) and aromatase inhibitors (31-34), respectively, in 
order to expand the therapeutic window for growth hormone 
treatment, especially in older males.  
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REVIEW OF LITERATURE 
1. A descriptive observational study was carried out by Choudhri, 
et al(35) at Kolkata from August 2006 to December 2009 in 
endocrine out patient department of RGKar Medical College, a 
tertiary care teaching institution in the eastern part of India 
involving the children and adolescents referred to the clinic for 
their growth failure. 
 The objectives of the this study was to 
a) Determine the magnitude of SS among the patients attending a 
tertiary referral centre 
b) Ascertain the pattern of SS, and  
c) Find out the etiological profile of SS. 
 Consecutive patients who attended the clinic with the 
complaints of growth delay were included in the study. With informed 
consent, detailed history, clinical examination and laboratory 
investigations were carried out and information was gathered by 
administering predesigned and pretested questionnaire. Diagnosed 
short statured cases were followed up for one year. 
Totally 164 short-statured boys and girls were screened out of 
the 2170 total attendees of the target group. Thus, the proportion of the 
SS was calculated to be 8%. 
25 
 
 CHOUDHURY, et al 
Sample size 164 
Place of study Endo OPD, kolkata 
Male to female ratio 1:1.2 
Hypothyroidism 29% 
GH deficiency 15% 
Chromosomal disorders 20% 
Normal variants 18% 
 
GH deficiency and hypothyroidism were found to be the 
commonest cause (26%) of SS among boys. In contrast, chromosomal 
anomalies were revealed to be the commonest cause (32%) in girls 
closely followed by hypothyroidism (31%). GHD was the most 
common cause among boys (26%) compared to chromosomal 
anomalies (32%) and hypothyroidism (31%) among their counterpart.  
2. Another prospective study was conducted by S.K.BHADADA, 
et al(36) from February 1999 to march 2001 in endocrine clinic at 
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tertiary referral centre, S.S. Hospital,Institute of medical 
sciences, BHU, Varanasi.  
 Bhadada, et al 
Sample size 352 
Male : female ratio 1.2 : 1 
Common age group 13 to 18 years 
Normal variants 36.1% 
FSS 15.09% 
CGD 21.02% 
Birth Asphyxia 8.52% 
Endocrine Causes 30.09% 
 
             A total of 352 patients of growth retardation have been 
studied. Of these 194 (55.11%) were males and 158(44.89%) were 
females. Majority of the patients were seen between the age group of 
13 to 18 years. Females outnumbered males in the age group of >18 
years. In the remaining age groups male to female ratio was almost 
equal. 
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 Normal variant short stature (36.1%) [Constitutional growth 
delay (21.02%) and familial short stature (15.09%)] were the most 
common causes of short stature followed by endocrine causes 
(30.09%), IUGR and birth anoxia (8.52%), chronic systemic diseases 
(7.38%), metabolic bone disease (5.68%) and malnutrition (5.1%). 
Miscellaneous causes contributed to 6.25%. 
The common cause of short stature in male was constitutional 
growth delay followed by hypothyroidism, miscellaneous causes, 
systemic diseases, and familial short stature, GH deficiency , mal 
nutrition and pan hypopituitarism. Familial short stature, Turner 
syndrome and hypothyroidism were accounted for common causes of 
short stature in females.  
3. In a cross sectional descriptive study which was conducted by 
sheidey assar, et al (37), the objective was to determine the 
frequency of GHD in children with short stature. All short 
stature children referred to endocrinology clinic of Golestan 
hospital in Ahvaz, Iran during 2005 to 2006 were included if 
they had height below 3rd percentile for age and sex, no any 
chronic disorder causing short stature and normal initial 
investigations. Standard GH stimulation tests were performed 
and patients with growth hormone maximum level of less than 
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10ng/dl (in two tests), were considered as growth hormone 
deficient. Out of 202 cases, 59.9% of them were male and 
40.1% of them were female with age range of 1 to 15.  
 Sheidey assar, et al 
Sample size 202 
SS-Male to female ratio 1.49:1 
GHD- Male to female ratio 2.4:1 
Mean age of SS 9.1 Years 
GHD 11.8% 
 
Family history of short stature was positive only in 4.2%. 
Height standard deviation score (SDS) of 75% of these cases was ≤ -3 
and weight for age in 79.2% was ≥ 10 percentile. These data showed 
significant difference between short and normal children (P < 0.05). 
They concluded the study by saying frequency of GH deficiency was 
average, compared to other studies. In children with SDS ≤ -3 and 
weight percentile ≥ 10, GH deficiency should be more considered. 
4. Another prospective study was designed by Heshmat moayeri, 
et al (38) in order to determine the etiologies of short stature with 
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especial concern on the prevalence of GH deficiency and to 
compare the results with world-wide studies. 
 Heshmat moayeri, et al 
Study population 4-18 years 
Sample size 426 
Mean age 10.8 years 
Male female ratio of SS 1.76:1 
Male female ratio of GHD 2 : 1 
Classic GHD 23.4% 
 
In total 426 subjects, boys were 272 and girls were 154 among 
4-18 years with short stature. The decision to investigate the growth 
hormone axis was taken with the knowledge that other explanations 
for growth failure have been excluded by documention of a normal 
full blood count, ESR, renal function and measurement of serum 
thyroxine concentration. In some female subjects, a karyotype was 
performed to exclude Turner’s syndrome. Bone age was studied in all 
subjects. 
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 They found that normal variants of growth including 
constitutional growth delay and familial short stature were identified 
as the most common causes of growth failure in this study. The results 
obtained in this study were in agreement with world-wide reports. 
Boys outnumbered girls by 2:1 (p < 0.05).They concluded that 
most children with short stature will not have an endocrine disorder, 
but in endocrine referral centers, the frequency of GH deficiency is 
higher than in general clinics and (2) GH deficiency appears to be 
more common in boys. 
5.  A prospective study on profile of growth hormone 
deficiency(40)  was done in Pediatric Endocrine Division, Bai 
Jerbai Wadia Hospital for Children, Institute of Child Health 
and Research Centre, mumbai by meena desai, et al. Of the              
430 children referred for the evaluation of SS, 100 (23%) were 
confirmed to have growth hormone deficiency. The male to 
female ratio was 1.94 : 1. Less than 10% belonged to the lower 
socio-economic group. Most of the cases (73%) presented 
between the ages of 6-15 years though growth failure was 
usually recognized earlier. 
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 Meena desai et al 
Sample size 430 
GHD 23% 
Common Age Group for SS 6-15 years 
Larons dwarfism 11% 
Abnormal presentation 24% 
Birth asphyxia 24% 
MPHD 12% 
Mean Peak level of GH in GHD  1.52 ± 1.36 
Mean Peak level of GH in Larons 62.8 ± 19.8 
        
Seventy five GH deficient children had idiopathic GH 
deficiency and 31% of these were familial .Fourteen had organic 
causes and 11 had GH resistance. 0f  the 75 with IGHD, 18 had 
abnormal deliveries, breech or birth asphyxia. Multitropic pituitary 
hormone deficiency was found in 9/75 cases of idiopathic GH 
deficiency and in three of the organic group. The height age was much 
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more retarded than chronological age in the GH resistant group (p ~ 
0.05) and the HA/BA ratio was also lowest in this group (p ~ 0.001). 
 The interesting feature of this study is the marked 
predominance of the familial cases (31%) and a high incidence of 
growth hormone resistant cases (11%). The mean peak levels of GH in 
normal controls were very significantly higher (20.1 + 1.36 ng/ml) 
than the mean peak levels of children with GH deficiency (1.52 + 1.36 
ng/ml). Very high peak levels (62.8 + 19.8 ng/ml) were obtained in the 
GH resistance group.  
In the GHR group the basal GH levels were noted to be high in  
6 of the 11 children ranging between 6 to 41 ng/ml (normal , 5 ng/ml) 
with a mean level of 26.2 ± 14 ng/ ml while as in the remaining five, 
the basal levels ranged between 1.28 to 4.93 ng/ ml, with a mean level 
of 3.47 ± 1.34 ng/ml. The levodopa + propranolol test (used as a 
second test in 24 GH deficiency children) showed a stimulated mean 
peak level of 1.1 ±  1.07 ng/ml and the mean peak level with insulin 
testing was 2.24 + 2.1 ng/ml in those children with GH deficiency 
where it was done as one of the two tests. A second test for GH was 
not necessary and was not done in the GH resistance group. 
       Colaco, et al54 found 57% of endocrine causes .Among this , 52% 
were due to GH deficiency. According to colaco, et al, a study 
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conducted in Bombay showed nutritional disorders and chronic 
systemic infections were the most common cause. Among endocrine 
causes, GH deficiency were seen in 97 (68%) and hypothyroidism in 
27 cases (18%) out of 143 cases. 
Suraj gupte55 found out that 10% of cases were due to endocrine 
cause of 300 consecutive children. Vimbani56 et al found severe GH 
deficiency in 1 per every 4000 children from a study of 48000 scottish 
school children. 
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AIM OF THE STUDY 
To study the following parameters in short stature children 
attending endocrine  OPD, ICH. 
a) Magnitude of SS among the patients attending a tertiary 
referral centre. 
b)  Ascertain the pattern of SS 
c) Find out the etiological and clinical profile of SS. 
d) Anthropometric measurements 
e) Dynamic GH study using clonidine stimulation test 
To find out the possible risk factors for short stature growth 
hormone deficiency. 
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STUDY JUSTIFICATIONS 
Short stature is a common pediatric endocrine problem. Since 
normal growth is a barometer of health in childhood, any child who is 
growing normally, virtually excludes chronic physical or mental 
illnesses. Hence, yearly evaluation of height and weight of all children 
is mandatory to assess their growth potential. The short stature, 
although not a disease per se, is a manifestation of several diseases. Its 
early diagnosis and treatment is most of the time rewarding. 
 Western literature is replete with studies on short stature; there 
are very few studies from Indian subcontinent. Since multiple factors 
viz. genetic, prenatal, postnatal and local environmental factors, affect 
the growth, their relative significance would be variable in different 
populations. 
 To study these etiological factors, present study has been 
designed. 
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MATERIALS AND METHODS 
Methodology: 
Study design – Descriptive  study 
Study period – Nov 2009 to oct 2011 
Study place – paediatric  endocrine  OPD,ICH  
Study population:  
Inclusion criteria 
1. Height <5TH percentile of Agarwal growth charts 
2. Growth rate below the fifth percentile for chronological 
age for local population ( Agarwal’s growth chart) 
3. Children referred to endocrine OPD as short stature . 
Exclusion criteria 
1. Those with height >5th percentile 
2. Any lab investigation showing rickets, liver disease, 
nutritional disease, chronic systemic infections & 
inflammation. 
3. Hypotensives. 
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Sample size - All children with the above inclusion criteria who  
   presented during the study period (84 cases).  
Ethical committee clearance was obtained from the Institutional 
review board. 
 
 
Maneuvre: 
Cases were recruited based on inclusion and exclusion criteria 
after obtaining informed parental consent. 
         Subjects with Ht <5th centile after excluding all systemic causes 
 
     Detailed history taking, thorough physical examination and 
investigations. 
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 (Symptoms to r/o systemic diseases, nutritional disorders, 
chronic infections, H/O consanguinity, family H/O short stature , APH 
mode of delivery, presenting part ,neonatal hyperbilirubinemia, 
development, hypoglycemic attacks, dysmorphic facies, constipation , 
history suggestive of increased ICP, genitalia examination & fundus 
examination) 
Anthropometric measurements 
(Standing height, upper segment, lower segment, arm span, SPL, 
height age and bone age)   
 
Upper segment/lower segment ratio   
 
                          Proportionate              disproportionate  
 
                 x – ray for bone age                  x-ray for bone age 
 
   Delayed           advanced     normal     delayed              normal   
   
Thyroid profile  Sr.17OHProgesterone Thyroid profile 
 
 
        Normal  
 
 
clonidine stimulation test 
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Standing height: 
It was measured on a height scale with heels, buttocks, 
shoulders and occiput against a vertical board and the head is 
positioned in Frankfurt plane (outer canthi of eyes at horizontal plane 
with upper border of tragus. The children were drawn upto their full 
height by upward pressure on the mastoids ). 
 
Arm Span: 
It was measured with the child standing, arms fully extended 
parallel to the floor and palms facing forward. With parent’s 
assistance, the distance between middle finger was measured using 
tape.  
 
Upper Segment, Lower Segment: 
The upper segment extends from vertex to pubis, lower segment 
extends from pubis to heel. First lower segment was measured and 
upper segment  derived by substracting LS from standing height. 
Height Age: 
Height age means the age which corresponds to the Ht. in cm 
along 50th centile curve. 
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Bone Age: 
 Bone age assessment was done on skiagram of pelvis, knees, 
left hand wrist, and left elbow following a standard chart based on a 
study at Radiology department of Institute Of Child Health and 
Hospital for Children, Chennai. 
Growth Formula: 
          Height age < bone age < chronological age – Familial SS 
          Bone age = height age < chronological age – CGD 
          Bone age < height age < chronological age – GH Deficiency 
Target height: 
 Growth is strongly related to the genetic potential. A child's 
midparental height is calculated as follows: 
¾ Girl = (height of mother in inches + height of father in 
inches)/2 - 2.5 inches 
¾ Boy = (height of mother in inches + height of father in 
inches)/2 + 2.5inches. 
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 This value plotted as adult height at 18 years and the spread for 
target range is 6 cm on either side of the target height. This then 
becomes target range and if the child’s height is within these 
percentiles, it is considered as normal. A short child who is growing 
close to his/her target height percentile is likely to have familial short 
stature. [15] . The child’s present height was projected along the 
percentile curve to get the anticipated adult height and correlated with 
mid parental height. Growth deceleration during the first 2 years 
followed by a normal growth velocity, with acceleration late in 
adolescence, leading to a final height that is close to the target height 
suggests constitutional delay in growth and development. 
 Auxological data mainly target height, child’s current height , 
height velocity and body proportions are some of the important tools 
for proper evaluation and management of SS. Judicious use of these 
techniques will reduce the cost of subsequent investigations.   
Clonidine stimulation test: 
In the morning after overnight fasting, 5 ml of venous sample 
was drawn for basal level of GH estimations. Then the child was given 
oral clonidine 
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4 microgram/kg body weight. Blood samples were drawn at 30 mins, 
60 mins, and 90 mins in three separate non-heparinised tubes. During 
the procedure, the subjects were kept in recumbent position and blood 
pressure were recorded half  hourly but no fall in BP were noted. 
 
Hormone assay : 
 Sera separated aliquated and stored at -20º C in a deep freezer 
until assayed. GH estimation was done at pediatric APOLLO Hospital 
using Radio-immunoassay (RIA) kit supplied by BARC. The tests 
cover a range of 0-40 ng of GH per ml of serum with an intra-assay 
and inter assay variability ranging between 5-10%. Only basal and 
post clonidine values were taken into account. Peak value >7 ng/ml is 
normal. Value <7 ng/ml-partial GHD and <3.5 ng/ml-complete GH 
deficiency. 
TSH assay was done in all subjects using the TSH Immuno 
Radiometric Assay (IRMA) kit supplied by BARC ,Bombay. The 
sensitivity is 0.07 microunits/ml. The TSH values taken as normal in 
ICH ,Egmore is 0.2-4 microunits /ml. 
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 IGF1 : IGF1 estimation was done to rule out pure GH deficiency, 
Larons dwarfism. 
MRI Brain : MRI Brain was done to rule out CNS pathology.   
STATISTICAL ANALYSIS: 
The parameters are evaluated using CHI SQUARE test and 
SPSS16 Version. P value < 0.05 is considered significant. 
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OBSERVATION 
Totally 84 children with short stature were studied in the age 
group less than 12 years. 
Demographic characteristics of children with short stature. 
Total no. of males  =  33(39.3%) 
Total no. of females  = 51(60.7%)   
Female predilection was observed.  The study population 
comprises 33 (39.3%) males and 51 (60.7%) females, there is no 
significant difference (p = 0.052) in male female distribution among 
the study population. 
 
Fig. 1Sex Distribution Among Children With Short Stature 
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             Fig.2 Etiological profile of short stature 
    Out of study population of 84 cases, most commonly observed 
etiology among endocrine causes was GH deficiency (53%) followed 
by constitutional growth delay (18%), hypothyroidism (11%), larons 
dwarfism (9%) & familial short stature (9%) .                                  
TABLE 1. AGE & SEX DISTRIBUTION IN STUDY 
POPULATION 
AGE GROUP MALE 
n =33 
FEMALE 
n =51 
TOTAL 
n = 84 
2-5 YEARS 11(44%) 14(56%) 25 (29.8%) 
6-9 YEARS 12(37.5%) 20(62.5%) 32 (38.1%) 
10-12 YEARS 10(58.8%) 17(41.2%) 27 (32.1%) 
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 Of the total study population, clustering (38.1%) of short stature noted 
in 6 to 9  years age group. Comparatively  lesser number of cases were 
affected with SS in 2 to 5 years (29.8%). 
 
Fig. 3 AGE AND SEX DISTRIBUTION OF SHORT STATURE 
 
TABLE 2. GHD distributioon among various age group 
Age group GHD Non GHD TOTAL P Value 
2-5 years 14 (26.4%) 
11 (35.5%) 
 
25 (29.8%) 
0.413 6-9 years 23 (43.4%) 
9 (29%) 
 
32 (38.1%) 
10-12 years 16 (30.2) 
11 (35.5%) 
 
27 (32.1%) 
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Maximum number of short stature were observed in 6 to 9 years 
group followed  by 10 to 12 years group. Whereas maximum cases of 
GH deficiency is seen in  6 to 9 years (43.4%)group followed by 10 to 
12 years group with 30.2% and finally 2 to 5 years group with 26.4%. 
The observed difference is statistically not significant (p=0.413). 
 Out of 53 children with GH deficiency, 14 (26.4%) were less 
than 5 year of age, 23(43.2%) belong to the age group 6 to 9 years ,16 
(18.2 %) belong to the age group 10 to 12 years. Out of 21 children 
with non GH deficiency causes, 11 (35.5%) were less than 5 year of 
age , 9(29%) belong to the age group 6 to 9 years ,11 (35.5 %) belong 
to the age group 10 to 12 years.  There is no significant difference in 
the distribution between these groups. 
                                          TABLE 3.AGE Vs SEX 
 
Chronological 
age 
n 
Minimum 
.age 
Maximum 
.age 
Mean ± SD
TOTAL 84 2 12 7.25 ± 3.33
Male 33   7.24 ± 3.26
Female 51   7.25 ± 3.41
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In this study of short stature, we had seen wide variations in age 
distribution ranging from 2 years to 12 years. Of total cases of short 
stature, mean age of presentation was 7.25 ± 3.33. It was almost 
similar in both sexes i.e.male-7.24 ± 3.26 and in female SS children                    
7.25 ± 3.41.  
 
Fig 4.SEX Vs Various diagnosis 
In GH deficiency, females were dominantly affected than 
males. Similar finding was observed in Larons dwarfism. Males were 
predominantly affected with hypothyroidism, constitutional growth 
delay. Both male and female were equally affected in  familial short 
stature.. 
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Table 4. Perinatal features & clinical symptom among children 
presented with short stature 
SYMPTOMS N Percentage 
Increased ICP 1 1.9% 
APH 5 9.4% 
Maternal Fever 9 16.9% 
Normal delivery 42 79.2% 
Pre Term  15 28.3% 
Birth asphyxia 33 39.3% 
Breech 58 69% 
NNH 15 17.9% 
Neonatal 
hypoglycaemia 
12 14.2% 
Consanguinity  49 58.3% 
Family history 8 9.5% 
Parental history of 
delayed puberty 
14 16.7% 
Microphallus  8 9.5% 
Hyper pigmented skin 10 11.9% 
Dysmorphic facies 41 48.8% 
Hypothyroidism  12 14.2% 
MPHD 10 11.9% 
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The study population was analysed based on their clinical 
symptoms  and presentation. We observed raised ICP in 1(1.9%), 
antepartum hemorrhage in 9.4%), maternal fever in 9 (16.9%)cases, 
normal delivery in 42 (79.2%), preterm delivery in 15 (28.3%), birth 
asphyxia in 33 (39.3%), breech presentation in 58 (69%), NNH in 15 
(17.9%), neonatal hypoglycemia in 12 (14.2%), consanguinity in 49 
(58.3%), family history in 8 (9.5%),parental history of delayed 
puberty in 14 (16.7%), microphallus in 8 (9.5%), hyperpigmented skin 
in 10 (11.9%), dysmorphic facies in 41 (48.8%), hypothyroidism in 12 
(14.2%) and MPHD in 10 cases(11.9%). 
TABLE 5.Comparison of breech delivery among GHD & non 
GHD group of children with short stature 
BREECH GHD ( n = 53) Non GHD(n = 31) P Value 
Present 28 (52.8%) 6(19.4%) 
0.005 
Absent  25(47.2%) 25(80.6%) 
 
28 cases were born with breech presentation of total 53 cases of 
GH deficiency. Whereas only 6 children born with breech presentation 
in non GH deficiency. .P value is 0.005 which is significant. 
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TABLE 6.Distribution of birth asphyxia in GHD vs. non GHD 
Birth asphyxia GHD (n = 53) Non GHD (n=31) P Value 
Present 26 (49.1%) 7 (22.6%) 
0.017 
Absent 27 (50.9%) 24(77.4%) 
 
Totally 26 cases suffered from birth asphyxia during delivery. P 
value is 0.017 which is significant. 
 
TABLE 7. Distribution of NNH in GHD 
Neonatal hyper- 
bilirubinemia GHD (n=53) 
Non GHD 
(n=31) P Value 
Present 13(24.5%) 2(6.9%) 
0.037 
Absent 40(75.5%) 29(93.1%) 
 
Totally 13 cases suffered from NNH during neonatal period. P 
value is 0.037 which is significant. 
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TABLE 8. Distribution of Birth Weight in Short Stature 
Birth weight Number Percentage 
Below 1 kg 2 2.38% 
1-1.5 kg 6 7.14% 
1.5-2 kg 8 9.52% 
2-2.5 kg 19 22.61% 
Above 2.5 kg 49 58.33% 
Total 84 100% 
 
Totally 49 cases out of 84 cases had relatively normal birth 
weight (BW>2.5kg) which contributes about 58.33%. Rest of them 
had low birth weight that comes around 41.67%.  
 
TABLE 9.Distribution of Consanguinity in GHD 
Consanguinity GHD (n=53) Non GHD (n=31) P Value 
Present 31(58.4%) 18(58.1%) 
0.970 
Absent 22(41.6%) 13(41.9) 
 
Totally 31 cases were born out of consanguineous marriage out 
of 53 cases of GHD. P value is 0.970 which is insignificant. 
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TABLE 10. Distribution of dysmorphic facies in GHD 
Dysmorphic 
facies GHD (n=53) 
Non GHD 
(n=31) P Value 
Present 41(77.3%) 0(0%) 
0.0 
Absent 12(22.7%) 31(100%) 
 
Totally 41 cases were born with dysmorphic facies (like midfacial 
crowding, central incisors, cleft lip & palate ) out of 53 cases of GHD. 
P value is 0.0 which is significant.  
TABLE 11. Clonidine stimulation test (CST) in short stature 
 
CST  n Mean ± SD 
GH – Basal 
GHD 45 1.45 ± 1.54 
Larons 
dwarfism 8 26.22 ± 13.98 
Non GHD 5 5.41 ± 4.29 
GH – 
Postclonidine 
GHD 45 1.99 ± 1.78 
Larons 
dwarfism 8 48.64 ± 11.63 
Non GHD 5 12.73 ± 11.78 
  
Observed mean value of basal GH level – 1.45 ± 1.54 in GHD, 
26.22 ± 13.98 in Larons,5.41 ± 4.29 in non GHD and mean 
postclonidine GH level – 1.99 ± 1.78 in GHD, 48.64 ± 11.63 in 
Larons, 12.73 ± 11.78 in non GHD. 
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TABLE 12. Clonidine stimulation test in true GHD & Larons 
dwarfism 
 
 
 
 GH basal 30 min 60 min 90 min
GHD(n=45) Mean ± SD 
1.45 ± 
1.55 
1.56 ± 
1.76 
2.19 ± 
2.19 
2.2 ± 
2.61 
Larons 
dwarfism(n=8) 
Mean ± 
SD 
26.21 ± 
13.98 
47.62 ± 
23.52 
49.99 ± 
15.44 
48.29 ± 
16.45 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 13. Various Auxological parameters in short stature 
 
 CA HA HA lag BA BA lag HA/BA HA/CA 
GHD 7.37 ± 3.06 ± 4.3 ± 3.96 ± 3.38 ± 0.95 ± 0.39 ± 
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(n=45) 3.35 2.09 2.36 2.63 2.02 0.89 0.18 
Larons 
Dwarfism  
(n=8) 
6.25 ± 
2.87 
1.96 ± 
1.92 
4.29 ± 
2.41 
2.69 ± 
1.49 
3.69 ± 
2.22 
0.63 ± 
0.34 
0.3 ± 
0.22 
Non 
GHD(31) 
7.34 ± 
3.47 
3.7 ± 
2.52 
3.66 ± 
1.59 
5.16 ± 
3.16 
2.24 ± 
1.66 
0.72 ± 
0.42 
0.45 ± 
0.19 
TOTAL 
(n=84) 
 
7.25 ± 
3.33 
3.19 ± 
2.27 
4.06 ± 
2.17 
4.29 ± 
2.84 
2.99 ± 
1.97 
0.83 ± 
0.71 
0.4 ± 
0.19 
 
HA / BA is useful in knowing the relative severity of retardation 
of one component over the other. The correlative study between      
HA / BA was analysed in the present study consisting of 3 groups GH 
deficiency, Larons dwarfism and non GHD and found to be 0.95,0.63 
and 0.72 respectively. We can make out that both mean height age and 
mean  bone age retarded in larons dwarfism than GHD. In both GHD 
and larons dwarfism, mean height age is more retarded than mean 
bone age. 
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Fig. 5 
This is graphical representation of mean level of GH secretion 
in response to oral clonidine at various intervals.  
 
 
                 
 
 
Fig.  6 
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In this figure, we can make out that both mean HA and mean 
BA retarded in larons dwarfism than GHD. In both GHD and larons 
dwarfism, mean HA is more retarded than mean BA. 
 
 
 
Of total study population, 21% of children had pituitary 
ypoplasia, 5% had pituitary aplasia, 3% had pituitary SOL, 3% had 
absent
 
 
 
 
h
 pituitary stalk whereas remaining 65% had normal MRI Brain 
study. 
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DISCUSSION 
        This descriptive study  Institute of Child Health 
rue GH deficiency 
re 
stature. 
stress to the 
victimised 43
44
 was conducted at
to find out the demographic characteristics , clinical  and etiological 
profile of short stature in children between 2 to 12 years of age 
attending endocrine OPD. 84 children between 2 to 12 years of age 
getting admitted at Institute of child health who met the inclusion and 
exclusion criteria were recruited. 
 We had  
1. 45 cases of (53.6%) t
2.  8 cases of (9.5 %) Larons dwarfism 
3. 9 cases of (10.7 %) hypothyroidism 
4. 8 cases of (9.5%)  familial short statu
5. 14 cases of (16.6%) constitutional short 
Short stature may be a disability and can be a di
 child or adolescent . So, short stature should be assessed 
early before the epiphysial fusion to get the opportunity of medical 
management. Extent of short stature as revealed in this study is higher 
than what was reported by Colaco et al.  i.e. a prevalence of 5.6% in 
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2500 children admitted in hospitals. Khadgawat et al45 have reported  
7% prevalence among 280 normal school children. Another 
observation made by Colaco revealed a prevalence of 10% short 
stature in children utilizing outpatient services. However, Garg 46 in 
his study of short stature in Indian Children had reported 13.8% 
prevalence of short stature, lesser than that of our study. In this study, 
the prevalence of  short stature was 15.6%. 
Bhadada et al reported normal variant
      
s as the predominant 
cause. Also they observed pituitary disorders in 19.2%, Celiac disease 
in 13.7% and Primary hypothyroidism among 13.7% cases of SS in 
2005-2007 compared to their findings of primary hypothyroidism in 
18.4%, pituitary disorders in 15.21% and nutritional disorders in 
17.4% cases of short stature in 1995-1996. This prevalence of pituitary 
disorders is comparable to our study which was 20.2%. Whereas 
prevalence of hypothyroidism is 11% which is lesser than that of 
Bhadada et al study (18.4%). This variation in etiological profile could 
be due to difference in study population, cultural practices and health 
care facilities. The changing trend is reported to be due to high index 
of suspicion and wider availability of screening tests.47 
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 Eventhough both studies were conducted at endocrinology 
OPD, there is wide variation in 
35
ue to difference 
in study population, cultural practic
wider availability of screening tests.  
 CHOUDHURY, et al In our study 
Sample size 164 84 
P  Endo OPD, Kolkata Endo OPD, 
Chennai 
lace of study
Male to female ratio 1:1.2 1:1.54 
Hypothyroidism 29% 10.7% 
GHD 15% 63.1% 
Norm ants al vari 18% 26.1% 
etiology.In our study, the most 
common cause is GH deficiency followed by normal variants of 
growth delay and hypothyroidism. Whereas Choudhury, et al study 
showed hypothyroidism as primary cause of short stature followed by 
normal variants of growth delay and GH deficiency.  
 This variation in etiological profile could be d
es and health care facilities .The 
changing trend is reported to be due to high index of suspicion and 
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 Bhadada, et al In our study 
Sample size 352 84 
Male : female ratio 1.2 : 1 1:1.54 
Common age group 13 to 18 years 6 to 9 years 
Normal variants 36.1% 26.1% 
FSS 15.09% 9.5% 
CGD 21.02% 16.6% 
Birth Asp yxia h 8.52% 39.3% 
Endocrin  e Causes 30.09% 73% 
There is female preponderance observed in our study in contrast 
to dy where ale predominan s seen. 
Comm
 Bhadada et al  stu  slight m ce36 i
on age group cannot be compared since their study populations 
were upto 18 years. Our study population is between 2 to 12 years. 
Bhadada et al study showed normal variants of growth delay as most 
common cause followed by endocrine causes. Etiological profile could 
not be compared because sample size is large in their study. Both 
studies were done at different periods of time in different population. 
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 Sheidey assar37, et 
al 
In our study 
Sample size 84 202 
SS-Male to female 
1.49:1 1:1.54 
ratio 
GHD- Male to female 
ratio 
2.4:1 1:1.52 
Mean age of SS 9.1 Years 7.25 years 
GHD 11.8% 63.1% 
 
            In by shiedey assar et al, GH deficiency incidence 
as 11.8% which was more commonly seen in males as general short 
a study done 
w
stature incidence. Here GH deficiency incidence is much lower than 
our study. In contrast to their study, females were more commonly 
affected than males in our populations.  
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Heshmat moayeri38, et 
In our study 
al 
Study population 4-18 years 2-12 years 
Sample size 426 84 
Mean age 10.8 years 7.25 years 
Male female ratio 1.76:1 1:1.54 
Classic GHD 23.4% 53.6% 
 
Heshmat et al found that males outnumbered females in classic 
GH deficiency whereas in our study females were predominantly 
affected. They conducted study in large population of short stature . 
And our sample size was only 84. So further studies need to be 
conducted in larger population in our country. 
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Meena desai40, et 
al 
In our study 
Sample size 430 84 
GHD 23% 63.1% 
Common Age Group for 
SS 
6-15 years 6 To 9 years 
Larons dwarfism 11% 9.5% 
Abnormal presentation 24% 52.8% 
Birth asphyxia 24% 49.08% 
MPHD 12% 18.8% 
Mean Peak level of GH in 
GHD 
1.52 ± 1.36 1.99 ± 1.78 
Mean Peak level of GH in 
Larons 
62.8 ± 19.8 48.64 ± 11.63 
In general, we had higher number of cases as GH deficiency 
which was the most common endocrine cause in our study because the 
study was done at ICH which is a tertiary referral centre and most of 
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the normal variants of growth disorders would have been screened  at 
peripheral hospital itself. Only those with pathological short stature  
would have been referred to higher centres. Hence we had higher 
incidence of GH deficiency rather than normal variants of growth 
delay. 
 Perinatal insults like birth asphyxia were found in 33 
cases(62.3%) of GH deficiency in the present study similar to the 
Western studies (48,49) which observed 50-60% incidence. 
Familial clustering was observed in 9.5% in the present study, 
less than that  observed in Bombay based study (31%)50  but more than 
that was observed by western investigators (3-5%)48,51. 
High incidence of consanguineous parentage (58.3%) was 
observed in the present study. This is much higher than any other 
previous Indian studies. One interesting finding observed was that 
consanguineous parentage was found in all the cases due to GH 
insensitivity syndromes. William et al52 also found similar incidence.  
Even though the typical features of GH deficiency was found  in 
48.8% of cases , the truncal  obesity was found only in one  case. This 
may be due to the associated nutritional and environmental insults in 
our country. 
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Unlike previous Indian studies, the maximum number of short 
children presented in the 6 to 9 years age group (64.3%). This is due to 
lack of awareness and lack of insight which postponed the desire to 
seek medical advice. 
There were 10 cases who had history suggestive of 
hypoglycemic attacks. Herber et al52 identified 11 children with 
hypoglycemic attacks out of 29 GH deficiency children, all of them 
were less than 2 years old. 
All the male children in the present study were noticed to have 
microphallus similar to previous studies.   
According to Kaplan et al53 , the degree of delay in bone age in 
GH deficiency is usually equivalent to delay in height age. But in the 
present study the retardation of height age was more severe than that 
of  bone age. 
Colaco et al50  in his study of 100 cases of GH abnormalities, 
found height age was more severely retarded than bone age in Larons 
dwarfism unlike GH deficiency. In the present study, it was observed 
more severe retardation of HA in both GHD and Larons dwarfism. 
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 LIMITATIONS 
 
 
¾ The sample size is small. 
¾ The study was done at a tertiary care centre ,So the study 
population does not reflect the general population. 
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SUMMARY 
 
The assessment of linear growth is one of the most sensitive 
means of evaluating all overall wellbeing of a child because ir gives a 
net expression of genetic make up, adequacy of nutrition, environment 
and residual effect of previous disease. Expression of stature in 
childhood is reinforced by GH,Thyroxine, sex steroids,cortisol and 
various growth factors. 
Recent development in pediatric endocrinology has thrown light 
on the actions of growth hormone and growth factors. Understanding 
its significance will pave way for proper approach to short stature 
children. 
A descriptive study on Epidemiology, Clinical profile , Etiology 
of short stature children aged 2 to 12 years was conducted in the 
department of pediatric endocrinology. 84 children diagnosed to have 
pathological short stature met the inclusion and exclusion criteria and 
they were recruited for the study after obtaining informed consent. 
Details regarding clinical history and relevant investigations were 
entered in prestructured proforma. The proportion of various outcome 
measures were arrived and statistical analysis done using Chi Square 
test . P value < 0.05 was considered significant. 
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CONCLUSION 
In children who attended endocrine OPD with pathological 
short stature were analysed for etiological and clinical profile. This 
study shows true growth hormone deficiency as the most common 
cause followed by normal variants of growth delay and 
hypothyroidism. 10(18.6%) out of 53 cases of GH deficiency had 
MPHD.  
Of GH deficiency children, statistically significant proportion of 
children had association with breech presentation, birth asphyxia, 
neonatal hypoglycemia and hyperbilirubinemia. Significant number of 
persons had hypoplastic or absent pituitary in MRI Brain. Severity of 
growth delay is more evident with larons dwarfism than GH 
deficiency while considering its low HA/BA ratio. MRI Brain plays 
vital role in making etiological diagnosis of short stature. 
We conclude that the findings can frame our mindset to remain 
vigilant about the problem for detection at its earliest stage for getting 
maximum benefit from available treatment. In endocrine referral 
centers, the frequency of GHD is higher than in general clinics. 
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RECOMMENDATIONS 
We can do screening for growth hormone deficiency selectively if a 
child had history of abnormal presentations, birth asphyxia, neonatal 
hypoglycemia and hyperbilirubinemia and features of midfacial 
crowding. 
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 ANNEXURE 
PATIENT DATA FORM 
 
 
Patient name: 
Age / sex: 
Endocrine no:                                 
Address: 
 
Date:  
SE status: 
CLINICAL HISTORY 
 
SYNCOPE YES / NO 
CONSTIPATION YES / NO 
POLYUREA YES / NO 
FEVER / LETHARGY YES / NO 
SEIZURES YES / NO 
PRECOCIOUS PUBERTY YES / NO 
DEFORMITIES YES / NO 
TRAUMA YES / NO 
TREATMENT HISTORY  
FEATURES OF IINCREASED 
ICP YES / NO 
VISUAL DISTURBANCES YES / NO 
 
OBTRETIC HISTORY: 
ANTENATAL HISTORY: 
FEVER / RASHES YES / NO 
DRUG INTAKE YES / NO 
    SPECIFY IF ANY  
MATERNAL ILLNESS YES / NO 
    SPECIFY IF ANY  
ANTEPARTUM YES / NO 
 
 HEMARRHAGE 
MODE OF DELIVERY NATURAL / LSCS /FORCEPS 
PRESENTING PART VERTEX / BREECH 
BIRTH WEIGT  
BIRTH ASPHYXIA YES / NO 
NEONATAL 
HYPERBILIRUBINEMIA YES / NO 
 
MATERNAL HISTORY: 
PUBERTY AGE  
MATERNAL SMOKING / 
ALCOHOL YES / NO 
 
FAMILY HISTORY: 
CONSANGUINITY  
FAMILY H/O SHORT 
STATYRE 
 
\ 
 FATHER MOTHER SIBLING 
HEIGHT    
PERCENTILE    
PUBERTAL 
AGE 
   
 
MID PARENTAL HEIGHT  
DIETIC HISTORY  
ANTHROPOMETRY PERCENTILE CHART 
HEIGHT  
WEIGHT  
ARM SPAN  
UPPER SEGMENT  
LOWER SEGMENT  
US / LS RATIO  
HEIGHT AGE  
 
 
 EXAMINATION: 
MIDLINE DEFECTS  
GENITALIA  
CRYPTORCHIDISM  
HYPERPIGMENTED SKIN  
FUNDUS  
DENTAL EXAM  
BP  
 
HORMONAL STUDIES 
THYROID 
PROFILE 
TSH T4 T3 
    
 
CLONIDINE 
STIMULATION 
TEST 
BASAL 30 MINS 60 MINS 90 MINS 
GH LEVEL     
 
BLOOD INVESTIGATION : IGF1 level in serum 
                                                   Sr.CORTISOL: 
                                                   Sr.ACTH : 
                                                   KARYOTYPING if indicated: 
RADIOLOGY : X RAY FOR AGE 
                             MRI SCAN.  
 
 
 
 INFORMED CONSENT FORM 
I agree to participate in the study titled “Pattern of endocrine
causes of short stature among children, 2-12 years of age in a urban
referral centre”. 
I confirm that I have been told about this study in my mother
tongue (Tamil) and I had the opportunity to ask question. I confirm
that I have been told about the risk and potential benefits of my child’s
participation. 
I understand that my child participation is voluntary and I may
refuse to continue at any time without giving any reason if i think my
child’s benefit is being affected. 
I agree not to restrict the use of any data or results that arise from
this study. 
1. Name of the child   : 
2. Name of guardian/care giver : 
Signature : 
Date  :  
3. Name of the witness  : 
Signature :  
Date  : 
4. Name of investigator  : 
Signature : 
Date  : 
 
 
 
  
 
 
 
  
 
 
 
  
 
 
ABBREVIATIONS 
 
 
IGF  -  insulin like growth factor 
IGFBP3 -  insulin growth factor binding protein 3 
GHD -  growth hormone deficiency 
GHRH - growth hormone releasing hormone 
GH  - growth hormone 
hGH  -  human growth hormone 
rhGH - recombinant growth hormone 
FSS  - familial short stature 
CGD  - constitutional growth delay 
MPHD - multiple pituitary hormone deficiency 
 
 
 
 
 
 
  
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
